Total Payments
$2,396
2019 Payments
$220.89
Companies
3
Transactions
11
Payment Breakdown by Category
Research$2,280 (95.2%)
Food & Beverage$115.89 (4.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2,280 | 9 | 95.2% |
| Food and Beverage | $115.89 | 2 | 4.8% |
Payments by Type
Research
$2,280
9 transactions
General
$115.89
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $2,280 | 9 | $0 (2019) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $76.02 | 1 | $0 (2019) |
| GE HEALTHCARE | $39.87 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $220.89 | 3 | Validus Pharmaceuticals LLC ($105.00) |
| 2018 | $900.00 | 3 | Validus Pharmaceuticals LLC ($900.00) |
| 2017 | $1,275 | 5 | Validus Pharmaceuticals LLC ($1,275) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/22/2019 | GE HEALTHCARE | — | Food and Beverage | Cash or cash equivalent | $39.87 | General |
| 05/13/2019 | Bausch & Lomb, a division of Bausch Health US, LLC | ULTRA (Device) | Food and Beverage | In-kind items and services | $76.02 | General |
| Category: OPHTHALMOLOGY | ||||||
| 02/13/2019 | Validus Pharmaceuticals LLC | Equetro (Drug) | — | Cash or cash equivalent | $105.00 | Research |
| Study: "A Phase IV Unequal Randomization Double-Blind Study To Evaluate the Dose Tolerance and Safety of Extended-Release Equetro (carbamazepine) versus Placebo Followed by an Open-Label and Long Term-Maintenance Treatment in Children and Adolescents Aged 10-17 years Diagnosed with Acute Manic or Mixed Bipolar I Disorder" • Category: CNS | ||||||
| 10/11/2018 | Validus Pharmaceuticals LLC | Equetro (Drug) | — | Cash or cash equivalent | $270.00 | Research |
| Study: "A Phase IV Unequal Randomization Double-Blind Study To Evaluate the Dose Tolerance and Safety of Extended-Release Equetro (carbamazepine) versus Placebo Followed by an Open-Label and Long Term-Maintenance Treatment in Children and Adolescents Aged 10-17 years Diagnosed with Acute Manic or Mixed Bipolar I Disorder" • Category: CNS | ||||||
| 06/30/2018 | Validus Pharmaceuticals LLC | Equetro (Drug) | — | Cash or cash equivalent | $390.00 | Research |
| Study: "A Phase IV Unequal Randomization Double-Blind Study To Evaluate the Dose Tolerance and Safety of Extended-Release Equetro (carbamazepine) versus Placebo Followed by an Open-Label and Long Term-Maintenance Treatment in Children and Adolescents Aged 10-17 years Diagnosed with Acute Manic or Mixed Bipolar I Disorder" • Category: CNS | ||||||
| 03/31/2018 | Validus Pharmaceuticals LLC | Equetro (Drug) | — | Cash or cash equivalent | $240.00 | Research |
| Study: "A Phase IV Unequal Randomization Double-Blind Study To Evaluate the Dose Tolerance and Safety of Extended-Release Equetro (carbamazepine) versus Placebo Followed by an Open-Label and Long Term-Maintenance Treatment in Children and Adolescents Aged 10-17 years Diagnosed with Acute Manic or Mixed Bipolar I Disorder" • Category: CNS | ||||||
| 12/31/2017 | Validus Pharmaceuticals LLC | Equetro (Drug) | — | Cash or cash equivalent | $345.00 | Research |
| Study: "A Phase IV Unequal Randomization Double-Blind Study To Evaluate the Dose Tolerance and Safety of Extended-Release Equetro (carbamazepine) versus Placebo Followed by an Open-Label and Long Term-Maintenance Treatment in Children and Adolescents Aged 10-17 years Diagnosed with Acute Manic or Mixed Bipolar I Disorder" • Category: CNS | ||||||
| 08/31/2017 | Validus Pharmaceuticals LLC | Equetro (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: "A Phase IV Unequal Randomization Double-Blind Study To Evaluate the Dose Tolerance and Safety of Extended-Release Equetro (carbamazepine) versus Placebo Followed by an Open-Label and Long Term-Maintenance Treatment in Children and Adolescents Aged 10-17 years Diagnosed with Acute Manic or Mixed Bipolar I Disorder" • Category: CNS | ||||||
| 06/05/2017 | Validus Pharmaceuticals LLC | Equetro (Drug) | — | Cash or cash equivalent | $220.00 | Research |
| Study: "A Phase IV Unequal Randomization Double-Blind Study To Evaluate the Dose Tolerance and Safety of Extended-Release Equetro (carbamazepine) versus Placebo Followed by an Open-Label and Long Term-Maintenance Treatment in Children and Adolescents Aged 10-17 years Diagnosed with Acute Manic or Mixed Bipolar I Disorder" • Category: CNS | ||||||
| 03/31/2017 | Validus Pharmaceuticals LLC | Equetro (Drug) | — | Cash or cash equivalent | $430.00 | Research |
| Study: "A Phase IV Unequal Randomization Double-Blind Study To Evaluate the Dose Tolerance and Safety of Extended-Release Equetro (carbamazepine) versus Placebo Followed by an Open-Label and Long Term-Maintenance Treatment in Children and Adolescents Aged 10-17 years Diagnosed with Acute Manic or Mixed Bipolar I Disorder" • Category: CNS | ||||||
| 01/30/2017 | Validus Pharmaceuticals LLC | Equetro (Drug) | — | Cash or cash equivalent | $130.00 | Research |
| Study: "A Phase IV Unequal Randomization Double-Blind Study To Evaluate the Dose Tolerance and Safety of Extended-Release Equetro (carbamazepine) versus Placebo Followed by an Open-Label and Long Term-Maintenance Treatment in Children and Adolescents Aged 10-17 years Diagnosed with Acute Manic or Mixed Bipolar I Disorder" • Category: CNS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| "A Phase IV Unequal Randomization Double-Blind Study To Evaluate the Dose Tolerance and Safety of Extended-Release Equetro (carbamazepine) versus Placebo Followed by an Open-Label and Long Term-Maintenance Treatment in Children and Adolescents Aged 10-17 years Diagnosed with Acute Manic or Mixed Bipolar I Disorder" | Validus Pharmaceuticals LLC | $2,280 | 9 |
About Dr. Mark Johnson, MD
Dr. Mark Johnson, MD is a Pediatrics healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1497796957.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Johnson, MD has received a total of $2,396 in payments from pharmaceutical and medical device companies, with $220.89 received in 2019. These payments were reported across 11 transactions from 3 companies. The most common payment nature is "" ($2,280).
Ad
Practice Information
- Specialty Pediatrics
- Other Specialties Pediatric Cardiology
- Location Saint Louis, MO
- Active Since 06/08/2006
- Last Updated 04/25/2024
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1497796957
Products in Payments
- Equetro (Drug) $2,280
- ULTRA (Device) $76.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Saint Louis
Dr. Philip Spinella, Md, MD
Pediatrics — Payments: $286,187
Pediatrics $286,187
Dr. David Balzer, Md, MD
Pediatrics — Payments: $209,718
Pediatrics $209,718
Dr. Amy Clark, Do, DO
Pediatrics — Payments: $129,192
Pediatrics $129,192
Dr. Jennifer Silva, Md, MD
Pediatrics — Payments: $128,336
Pediatrics $128,336
Dr. Nico Dosenbach, Md, MD
Pediatrics — Payments: $115,400
Pediatrics $115,400
Dr. Kel Vin Woo, M.d., Ph.d, M.D., PH.D
Pediatrics — Payments: $100,017
Pediatrics $100,017